General MedicationsINJECTIONGeneric

ZOSYN

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

Standard Dose

EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

Max Dose

Refer to approved labeling

Primary Use

Review priority: STANDARD Marketing status: Discontinued

Summary

Approval overview ZOSYN is listed in Drugs@FDA under application 050684 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient PIPERACILLIN SODIUM; TAZOBACTAM SODIUM Form and strength INJECTABLE;INJECTION - EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor WYETH PHARMS Submission history Latest submission status date: 2024-12-03 00:00:00.

Structured Monograph

Clinical summary

Approval overview ZOSYN is listed in Drugs@FDA under application 050684 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient PIPERACILLIN SODIUM; TAZOBACTAM SODIUM Form and strength INJECTABLE;INJECTION - EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor WYETH PHARMS Submission history Latest submission status date: 2024-12-03 00:00:00. Submission type: SUPPL.

Monitoring

• Marketing status: Discontinued
• Review priority: STANDARD

Interaction Notes

No interaction notes stored yet.